Reata Pharmaceuticals (RETA): Reiterating Rating And PT As CATALYST Trial Gets Off The Ground - Piper Jaffray
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Reata Pharmaceuticals (NASDAQ: RETA) after the company announced it dosed the first CTD-PAH patient in its Phase III CATALYST trial of lead candidate bardoxolone.
The analyst is encouraged to see CATALYST get off the ground and his research suggests that there is high investigator/patient interest in the program and that this is a conservatively powered,capital-efficient, trial which should accelerate to deliver pivotal results by early ’18.
Reata also announced expanded results from a larger group of CTD-PAH patients (now n=22, up from single digits) treated in the Phase II LARIAT trial. The analyst views this update as addressing key investor questions on replicability of results with Bard, as well as risk-reducing for CATALYST in terms of having well-informed the powering, dosing and patient selection, for the study.
No change to the price target of $33.
Shares of Reata Pharmaceuticals closed at $28.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix (NFLX) PT Raised to $165.00 at Oppenheimer
- Cowen On Skyworks (SKWS): Co. Will Ride iPhone Super-Cycle But We Prefer Qorvo (QRVO)
- IBM (IBM) PT Raised to $175 at JMP Securities Following Q4 2016 Earnings Report
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesPiper Jaffray, Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!